Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | BIO |
|---|---|---|
| Founded | 2013 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 8.7B |
| IPO Year | 2020 | N/A |
| Metric | PCVX | BIO |
|---|---|---|
| Price | $51.72 | $294.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $105.00 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 1.1M | 199.1K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,557,500,000.00 |
| Revenue This Year | N/A | $1.62 |
| Revenue Next Year | N/A | $2.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.66 | $211.43 |
| 52 Week High | $93.77 | $373.69 |
| Indicator | PCVX | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 33.47 |
| Support Level | $44.85 | $293.94 |
| Resistance Level | $56.04 | $316.63 |
| Average True Range (ATR) | 2.65 | 8.98 |
| MACD | 0.76 | -2.68 |
| Stochastic Oscillator | 74.09 | 0.72 |
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.